vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $182.4M, roughly 1.1× Climb Global Solutions, Inc.). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 1.8%, a 6.4% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 12.9%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 19.1%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
CLMB vs COLL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $205.4M |
| Net Profit | $3.3M | $17.0M |
| Gross Margin | 14.5% | 62.5% |
| Operating Margin | 2.1% | 29.6% |
| Net Margin | 1.8% | 8.3% |
| Revenue YoY | 32.1% | 12.9% |
| Net Profit YoY | -9.5% | 35.3% |
| EPS (diluted) | $0.18 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $205.4M | ||
| Q3 25 | $161.3M | $209.4M | ||
| Q2 25 | $159.3M | $188.0M | ||
| Q1 25 | $138.0M | $177.8M | ||
| Q4 24 | $161.8M | $181.9M | ||
| Q3 24 | $119.3M | $159.3M | ||
| Q2 24 | $92.1M | $145.3M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $17.0M | ||
| Q3 25 | $4.7M | $31.5M | ||
| Q2 25 | $6.0M | $12.0M | ||
| Q1 25 | $3.7M | $2.4M | ||
| Q4 24 | $7.0M | $12.5M | ||
| Q3 24 | $5.5M | $9.3M | ||
| Q2 24 | $3.4M | $19.6M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 62.5% | ||
| Q3 25 | 15.9% | 61.7% | ||
| Q2 25 | 16.5% | 57.7% | ||
| Q1 25 | 16.9% | 54.8% | ||
| Q4 24 | 19.3% | 54.0% | ||
| Q3 24 | 20.3% | 60.8% | ||
| Q2 24 | 20.2% | 62.5% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 29.6% | ||
| Q3 25 | 4.3% | 29.7% | ||
| Q2 25 | 5.0% | 18.7% | ||
| Q1 25 | 3.5% | 12.2% | ||
| Q4 24 | 7.2% | 20.9% | ||
| Q3 24 | 7.1% | 21.9% | ||
| Q2 24 | 4.6% | 32.7% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 8.3% | ||
| Q3 25 | 2.9% | 15.0% | ||
| Q2 25 | 3.7% | 6.4% | ||
| Q1 25 | 2.7% | 1.4% | ||
| Q4 24 | 4.3% | 6.9% | ||
| Q3 24 | 4.6% | 5.9% | ||
| Q2 24 | 3.7% | 13.5% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.48 | ||
| Q3 25 | $1.02 | $0.84 | ||
| Q2 25 | $1.30 | $0.34 | ||
| Q1 25 | $0.81 | $0.07 | ||
| Q4 24 | $1.52 | $0.36 | ||
| Q3 24 | $1.19 | $0.27 | ||
| Q2 24 | $0.75 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $301.7M |
| Total Assets | $458.8M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $386.7M | ||
| Q3 25 | $49.8M | $285.9M | ||
| Q2 25 | $28.6M | $222.2M | ||
| Q1 25 | $32.5M | $197.8M | ||
| Q4 24 | $29.8M | $162.8M | ||
| Q3 24 | $22.1M | $120.0M | ||
| Q2 24 | $48.4M | $271.6M |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $301.7M | ||
| Q3 25 | $109.3M | $274.8M | ||
| Q2 25 | $105.2M | $232.2M | ||
| Q1 25 | $95.6M | $234.4M | ||
| Q4 24 | $90.6M | $228.8M | ||
| Q3 24 | $87.7M | $234.3M | ||
| Q2 24 | $79.8M | $216.6M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $1.7B | ||
| Q3 25 | $376.1M | $1.6B | ||
| Q2 25 | $420.7M | $1.6B | ||
| Q1 25 | $370.1M | $1.6B | ||
| Q4 24 | $469.2M | $1.7B | ||
| Q3 24 | $371.9M | $1.6B | ||
| Q2 24 | $302.8M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $123.0M |
| Free Cash FlowOCF − Capex | — | $122.4M |
| FCF MarginFCF / Revenue | — | 59.6% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $123.0M | ||
| Q3 25 | $22.2M | $78.4M | ||
| Q2 25 | $-2.2M | $72.4M | ||
| Q1 25 | $8.5M | $55.4M | ||
| Q4 24 | $16.0M | $84.6M | ||
| Q3 24 | $-3.6M | $-9.0M | ||
| Q2 24 | $7.3M | $67.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $122.4M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | — | $72.4M | ||
| Q1 25 | — | $54.6M | ||
| Q4 24 | — | $84.1M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $67.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.6% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 46.2% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | — | 46.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 7.25× | ||
| Q3 25 | 4.73× | 2.49× | ||
| Q2 25 | -0.37× | 6.05× | ||
| Q1 25 | 2.30× | 22.92× | ||
| Q4 24 | 2.29× | 6.75× | ||
| Q3 24 | -0.66× | -0.96× | ||
| Q2 24 | 2.13× | 3.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
